Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBUNASDAQ:DBVTNASDAQ:ENTANASDAQ:NLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$1.36-0.7%$1.07$0.66▼$3.00$126.49M2.481.33 million shs746,493 shsDBVTDBV Technologies$11.54+12.0%$9.36$2.20▼$12.78$316.05M-0.59191,181 shs29,062 shsENTAEnanta Pharmaceuticals$7.89-1.0%$6.49$4.09▼$17.24$168.69M0.84282,965 shs78,004 shsNLTXNeoleukin Therapeutics$20.09+1.7%$17.60$2.03▼$14.36$188.81M1.1150,104 shs75,550 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences-0.73%+0.74%+29.52%+77.20%-15.00%DBVTDBV Technologies+12.03%+25.29%+45.33%+77.52%+203.66%ENTAEnanta Pharmaceuticals-1.00%+5.06%+9.74%+66.81%-39.95%NLTXNeoleukin Therapeutics+2.92%+14.83%+11.27%+104.24%-45.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBUCaribou Biosciences2.3387 of 5 stars3.51.00.00.02.71.70.6DBVTDBV Technologies3.9038 of 5 stars4.43.00.00.03.32.50.6ENTAEnanta Pharmaceuticals4.1082 of 5 stars3.42.00.04.72.42.50.0NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences 3.00Buy$8.50525.00% UpsideDBVTDBV Technologies 2.80Moderate Buy$14.7527.83% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$18.00128.14% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DBVT, ENTA, NLTX, and CRBU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$21.006/3/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.005/29/2025DBVTDBV TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell$7.255/27/2025DBVTDBV TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/27/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.005/5/2025DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $16.005/1/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $15.004/28/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $3.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$9.92M12.75N/AN/A$2.79 per share0.49DBVTDBV Technologies$4.15M76.16N/AN/A$1.42 per share8.13ENTAEnanta Pharmaceuticals$67.64M2.49N/AN/A$6.08 per share1.30NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$149.10M-$1.62N/AN/AN/A-1,490.84%-55.70%-45.35%8/5/2025 (Estimated)DBVTDBV Technologies-$113.92M-$4.92N/AN/AN/A-3,249.99%-278.24%-140.54%7/29/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ALatest DBVT, ENTA, NLTX, and CRBU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025DBVTDBV Technologies-$0.28N/AN/AN/A$0.64 millionN/A5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/8/2025Q1 2025CRBUCaribou Biosciences-$0.43-$0.43N/A-$0.43$1.48 million$2.35 million4/11/2025Q4 2024DBVTDBV TechnologiesN/A-$1.10N/A-$1.10N/A$0.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A7.637.63DBVTDBV TechnologiesN/A0.720.72ENTAEnanta PharmaceuticalsN/A5.295.29NLTXNeoleukin TherapeuticsN/A15.3315.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%DBVTDBV Technologies71.74%ENTAEnanta Pharmaceuticals94.99%NLTXNeoleukin Therapeutics52.37%Insider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences8.28%DBVTDBV Technologies1.44%ENTAEnanta Pharmaceuticals13.89%NLTXNeoleukin Therapeutics1.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences10093.01 million85.30 millionOptionableDBVTDBV Technologies8027.39 million27.00 millionOptionableENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataDBVT, ENTA, NLTX, and CRBU HeadlinesRecent News About These CompaniesNeoleukin Therapeutics (NASDAQ:NLTX) Shares Down 7.5% - Should You Sell?July 1 at 12:54 AM | marketbeat.comNeoleukin Therapeutics (NASDAQ:NLTX) Stock Price Down 4.8% - Time to Sell?June 10, 2025 | marketbeat.com(NGNE) Proactive StrategiesOctober 18, 2024 | news.stocktradersdaily.comNNeurogene concludes merger deal with Neoleukin TherapeuticsDecember 20, 2023 | pharmaceutical-technology.comPIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 20, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitDecember 14, 2023 | finance.yahoo.comNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesDecember 4, 2023 | benzinga.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…October 5, 2023 | markets.businessinsider.comNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 26, 2023 | finanznachrichten.deNeoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%September 26, 2023 | dhakatribune.comDNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comInvesting in Neoleukin Therapeutics Inc. [NLTX]: What You Must KnowAugust 21, 2023 | knoxdaily.comKNeoleukin Therapeutics Recent Insider ActivityAugust 18, 2023 | benzinga.comBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncAugust 18, 2023 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXAugust 1, 2023 | markets.businessinsider.comRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics IncJuly 28, 2023 | finance.yahoo.comMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmJuly 26, 2023 | benzinga.comAnalysts review Neoleukin Therapeutics Inc.’s ratingJuly 26, 2023 | knoxdaily.comKALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCFJuly 24, 2023 | kentuckytoday.comKBaker Bros. Advisors Now Owns 19.99% of Neoleukin TherapeuticsJuly 24, 2023 | 247wallst.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not Hype3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedSuper Micro Computer Stock's Rally Backed by Strong FinancialsBy Gabriel Osorio-Mazilli | June 19, 2025View Super Micro Computer Stock's Rally Backed by Strong FinancialsA Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesBy Gabriel Osorio-Mazilli | June 6, 2025View A Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesSnag These 3 Bargain Tech Stocks Before They PopBy Gabriel Osorio-Mazilli | June 27, 2025View Snag These 3 Bargain Tech Stocks Before They PopDBVT, ENTA, NLTX, and CRBU Company DescriptionsCaribou Biosciences NASDAQ:CRBU$1.36 -0.01 (-0.73%) Closing price 07/3/2025 03:22 PM EasternExtended Trading$1.36 0.00 (0.00%) As of 07/3/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.DBV Technologies NASDAQ:DBVT$11.54 +1.24 (+12.03%) Closing price 07/3/2025 01:03 PM EasternExtended Trading$11.59 +0.05 (+0.43%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Enanta Pharmaceuticals NASDAQ:ENTA$7.89 -0.08 (-1.00%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Neoleukin Therapeutics NASDAQ:NLTX$20.09 +0.34 (+1.72%) As of 07/3/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
